#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
Switching Peptides: What the Evidence Says
No clinical guideline covers switching between incretin-class peptides. Prescribing information and early research both say: start at the lowest dose.
Which drugs flag for gastric motility risks
A 2026 study screened 58 million adverse-event reports. Semaglutide had the strongest signal for impaired gastric emptying.
Oral Wegovy tracker: FDA, EMA, MHRA
The FDA, EMA, and MHRA have now all approved oral Wegovy for weight management. Here is the regulatory timeline and how the three decisions compare.
Radiolabeling peptides in fewer steps
A 2026 study reports a hydroformylation method that installs carbon-14 or tritium labels on peptides, including semaglutide analogs.
Stopping semaglutide before abdominoplasty
A retrospective study of 80 patients finds that stopping semaglutide four weeks before abdominoplasty normalised complication rates.
Peptide Stacks With Tirzepatide
No clinical trial has studied BPC-157, TB-500, or CJC-1295 in combination with tirzepatide. Here is what the evidence shows.
Wegovy weight loss pill gets UK approval
The MHRA approved oral Wegovy (semaglutide 25 mg tablets) for weight management in adults on 11 June 2026, making it the first oral GLP-1 for obesity in the UK.
Optic neuropathy after semaglutide ramp-up
A 2026 case report describes atypical optic nerve damage behind the eye in a man on semaglutide 1 mg weekly, broadening the known spectrum of eye-related risks.
Biopsy-free MASH trials need longer runs
Ajmera and Loomba argue that NIT-based MASH trials must extend beyond 52 weeks and use composite non-invasive endpoints to capture fibrosis change.
Dulaglutide in 2026: still relevant?
A narrative review argues dulaglutide still earns its place in cardiometabolic care despite tirzepatide and semaglutide gaining ground.
GLP-1 add-on doubled time in range: Ramadan
A 2026 CGM study found that adding semaglutide or tirzepatide to insulin doubled time in range during Ramadan fasting without raising hypoglycaemia risk.
GLP-1 drugs cut CV risk in type 2 diabetes
A 2026 network meta-analysis finds GLP-1 therapies reduce mortality and MACE in type 2 diabetes. Semaglutide and albiglutide rank highest.